Information on EC 2.3.1.147 - glycerophospholipid arachidonoyl-transferase (CoA-independent)

CoA-IT

-

658381, 676922, 701639, 718983

CoAIT

-

Coenzyme A-independent transacylase

1-organyl-2-arachidonoyl-sn-glycero-3-phosphocholine + 1-organyl-2-lyso-sn-glycero-3-phosphoethanolamine = 1-organyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine + 1-organyl-2-lyso-sn-glycero-3-phosphocholine

Acyl group transfer

-

1-organyl-2-arachidonoyl-sn-glycero-3-phosphocholine:1-organyl-2-lyso-sn-glycero-3-phosphoethanolamine arachidonoyltransferase (CoA-independent)

Catalyses the transfer of arachidonate and other polyenoic fatty acids from intact choline or ethanolamine-containing glycerophospholipids to the sn-2 position of a lyso-glycerophospholipid. The organyl group on sn-1 of the donor or acceptor molecule can be alkyl, acyl or alk-1-enyl. The term 'radyl' has sometimes been used to refer to such substituting groups. Differs from EC 2.3.1.148 glycerophospholipid acyltransferase (CoA-dependent) in not requiring CoA and in its specificity for poly-unsaturated acyl groups.

102347-79-5

-

1-Acyl-glycerophosphocholine + diacylcholine glycerolipid

?

-

Substrates: -
Products: -

?

1-Acyl-glycerophosphoethanolamine

?

-

Substrates: ,transfer of 20:4 from diacylglycerophosphocholine
Products: -

?

1-Alkenyl-2-lysoglycerophospholipid + 1-acyl-2-arachidonoyl-glycerophosphocholine

1-Alkenyl-2-arachidonyl-glycerophospholipid + 1-acyl-2-lyso-glycerophosphocholine

-

Substrates: -
Products: -

?

1-Alkenyl-2-lysoglycerophospholipid + 1-alkyl-2-arachidonoyl-glycerophosphocholine

1-Alkenyl-2-arachidonoylglycerophospholipid + 1-alkyl-2-lyso-glycerophosphocholine

-

Substrates: -
Products: -

?

1-Alkenyl-glycerophosphoethanolamine + diacylglycerophosphocholine

?

-

Substrates: transfer of 20:4 from diacylglycerophosphocholine
Products: -

?

1-alkyl-2-lyso-glyceryl phosphorylcholine + oleoyl-CoA

?

-

Substrates: -
Products: -

?

1-alkyl-2-lyso-glyceryl-3-phosphorylcholine + 1-acyl-2-arachidonoyl-glyceryl-3-phosphorylcholine

1-alkyl-2-arachidonoylglycerophosphocholine + 1-acyl-2-lyso-glycerophosphocholine

-

Substrates: -
Products: -

?

1-Alkyl-2-lysoglycerophospholipid + 1-acyl-2-arachidonoyl-glycerophosphocholine

?

-

Substrates: -
Products: -

?

1-Alkyl-2-lysoglycerophospholipid + 1-alkyl-2-arachidonoyl-glycerophosphocholine

1-Alkyl-2-arachidonoylglycerophospholipid + 1-alkyl-2-lyso-glycerophosphocholine

-

Substrates: -
Products: -

?

1-Alkyl-glycerophosphocholine + diacylcholine glycerolipid

?

-

Substrates: -
Products: -

?

1-Alkyl-glycerophosphoethanolamine + diacylglycerophosphocholine

?

-

Substrates: transfer of 20:4 from diacylglycerophosphocholine
Products: -

?

Alkenyl-glycerophosphocholine + diacylcholine glycerolipid

?

-

Substrates: -
Products: -

?

additional information

?

-

15 entries

additional information

?

-

11 entries

(3S,4R)-[4-(Isobutenyloxy)-3-triphenylmethylamino]azetitin-2-one

-

i.e. SB 216754

16269

1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphocholine

-

16267

1-[2-[3-(4-Chloro-3-trifluoromethylphenyl)ureido]-4-trifluoromethyl phenoxy]-4,5-dichlorobenzene sulfonic acid

-

i.e. SK&F 45905

16266, 16267, 16270, 16271

4-methoxybenzyl(3S,4R)-6-bromo-6-[(1-methyl-1,2,3-triazol-4-yl)-hydroxymethyl]penicillanate

-

i.e. SB 212047

16269

Diethyl 7-(1,4,5-triphenyl imidazol-2-yloxy)heptane phosphonate

-

SK&F 98628

16267

Diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazol-1-yl)heptane-phosphonate

-

i.e. SK&F 98625

16266, 16267, 16270, 16271

diethyl dicarbonate

-

N-tosyl-L-phenylalanine chloromethyl ketone

-

NS-398

-

enzyme inhibition in cancer cell has an anti-carcinogenic effect and induces accumulation of unesterified arachidonic acid

676922

Phenylmethyl-sulfonyl fluoride

-

PLT-98625

-

enzyme inhibition in cancer cell has an anti-carcinogenic effect and induces accumulation of unesterified arachidonic acid

676922

SB-98625

-

i.e. SKF 98625 or diethyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hepatine phosphate, inhibitor blocks the replication of MDA-MB-231 cells in early to mid G1 phase, induces early rounding and occasional blebbing of the cells, but not late apoptosis, blistering, and lysis

SKF 98625

-

a reversible antagonist of CoA-IT, in vitro and in vivo inhibition, induces eosinophil apoptosis in vitro

701639

Triacsin C

-

enzyme inhibition in cancer cell has an anti-carcinogenic effect and induces accumulation of unesterified arachidonic acid

676922

additional information

-

inhibition of the enzyme attenuates the proliferation of breast cancer cell lines, intracellular level and distribution of free or triglyceride arachidonic acid, or an oxidized metabolite thereof, and blockage of remodeling are responsible for the effect, overview

-

interferon gamma

-

i.e. IFN-gamma, human, recombinant, increases enzyme activity in microsomes by about 100%

-

Tumor necrosis factor alpha

-

i.e. TNF-alpha, human, recombinant, 50% increase in enzyme activity within 30 min incubation of microsomes

-

0.0004

1-Alkyl-2-lyso-glyceryl-3-phosphorylcholine

-

additional information

-

-

0.005 - 0.025

SKF 98625

6.5 - 9

-

7.4

-

assay at

658221, 701639

37

-

assay at

-

-

-

-

Oryctolagus cuniculus

-

16275

-

alveolar macrophage

Oryctolagus cuniculus

-

16275

amnion

Ehrlich ascites carcinoma cell

-

WISH cell

-

-

-

-

-

-

-

-

-

-

estrogen receptor-positive breast cancer cell

-

i.e. mono-mac 6, monocytic cell line

-

-

-

-

-

-

-

-

Highest Expressing Human Cell Lines

Filter by:

Cell Line Links

Gene Links

metabolism

-

the enzyme participates in the high affinity-low capacity pathway. Cells use this pathway to rapidly incorporate and remodel arachinonic acid through various glycerophospholipids. The predominant enzymes in this pathway include long chain fatty-acid ligase, lysophospholipid: acyl-CoA acyltransferase, and acyl-CoA independent transacylase, overview

701639

physiological function

medicine

-

disruption of arachidonic acid remodeling in a manner that increases intracellular arachidonic acid level involving inhibition of the enzyme may represent a novel therapeutic strategy to reduce cancer cell proliferation

pharmacology